Table 1.

CLL Patient Characteristics

No	Sex	Age	RAI	ZAP 70	FISH	CD 38	IgVh status	LDH	ALC (K/uL)	Treatment
1	F	66	2	−	13q-	−	Mutated; VH4-4	241	564.48	R-Campath
2	F	66	1	+	13q-	+/−	Unmutated; VH1-18	211	214.13	none
3	F	65	1	+	13q-	+/−	Unmutated; VH1-18	207	203.04	None
4	F	64	1	−	13q-	−		212	94.6	none
5	F	64	1	−	13q-	−		206	80.37	none
6	M	73	3	−	13q-	−	Unmutated; VH3-48	160	234.62	None
7	M	73	3	−	13q-	−	Unmutated; VH3-48	182	354.47	None
8	M	52	2	−	13q-13q-	−	Unmutated; VH5-51	197	89	None
9	M	55	2	−	17p-13q-	−	Unmutated;VH1-69	144	163.875	None
10	F	65	2	+	17p- Tri12	−		305	121.4	R-CVP
11	F	64	2	+	17p- Tri12	−		195	90.25	R-CVP
12	M	58	1	−	13q-	−	Mutated; VH4-4	194	73.272	None
13	M	59	0	+	Tri 12	−	Unmutated; VH4-59	261	45.955	none
14	M	58	0	+	Tri 12	−	Unmutated; VH4-59	264	28.85	None
15	M	54	0	+	13q-	+	Borderline mutated; VH6-61	177	109.3	none
16	F	63	1	−	13q-13q-	−	Mutated VH3-23	237	169.63	None
17	M	59	0	−	13q-	−		236	119.5	None
18	M	71	2	−	13q-13q-	−		230	73.3	none
19	M	72	2	−	13q-13q-	−		150	65.87	none
20	F	66	3	+	5q-, 7q- del 3			225	30.4	FCRX2, ofatumumab,ONO/revlimid, azacitidine
21	F	65	0	−	none	−		172	61.4	none
22	M	56	1	−	13q-13q-	−	Mutated IgVH	141	110	none
23	M	76	3	−		−		216	60.16	Rituximab
24	M	58	0	−		−		153	51.8	None
25	F	78	3	+	17p-, mono 13,loss of IgH	−		273	46.718	R-bendamustine
26	F	63	1	+	13q-	−	IgVH unmutated	210	62.035	none
27	F	64	1	+	13q-	−	IgVH unmutated	211	45.36	none
28	M	59	3	+	Tri 12	−	IgVH unmutated	418	98.487	Campath/Rituxan
29	F	64	0		17p-	−	Mutated; VH4-4	195	35.752	none
30	M	67	1	+	11q-,13q-	+	IgVH unmutated	216	107.096	Camp/Rituxan
31	M	73	0	−	13q-	−		172	23.3	none
32	M	70	1	+	13q-, del ATM, IGH loss	+		195	15.6	none
33	F	56	0	+	13q-	−		167	76.6	none
34	F	66	0	−	13q-13q-	−	Mutated; VH2-23	190	16.3	none
35	F	76	0	−	13q-	−	Mutated; VH3-53	158	26.1	none